Many studies have shown that high MMP-11 expression is associated with poor clinical outcomes in lung cancer, colorectal cancer, hepatocellular carcinoma, osteosarcoma, prostate cancer and breast cancer [26–31]. This evidence concerns the gene MMP11 and prostate cancer.